Plus Therapeutics, Inc.

NasdaqCM:PSTV Stock Report

Market Cap: US$6.4m

Plus Therapeutics Management

Management criteria checks 2/4

Plus Therapeutics' CEO is Marc Hedrick, appointed in May 2004, has a tenure of 20.58 years. total yearly compensation is $1.13M, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $22.06K. The average tenure of the management team and the board of directors is 5.1 years and 4.4 years respectively.

Key information

Marc Hedrick

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage49.1%
CEO tenure20.6yrs
CEO ownership0.3%
Management average tenure5.1yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Oct 07

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Sep 22

Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02

Jul 21

CEO Compensation Analysis

How has Marc Hedrick's remuneration changed compared to Plus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$13m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023US$1mUS$556k

-US$13m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$21m

Dec 31 2022US$955kUS$535k

-US$20m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$2mUS$510k

-US$13m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$1mUS$510k

-US$8m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$867kUS$510k

-US$4m

Sep 30 2019n/an/a

-US$7m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018US$615kUS$510k

-US$11m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$19m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$846kUS$500k

-US$27m

Compensation vs Market: Marc's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.

CEO

Marc Hedrick (61 yo)

20.6yrs

Tenure

US$1,134,027

Compensation

Dr. Marc H. Hedrick, M.D., M.B.A., serves as President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
Marc Hedrick
President20.6yrsUS$1.13m0.35%
$ 22.1k
Andrew Sims
VP of Finance & CFO4.8yrsUS$539.23k0.17%
$ 10.6k
Desiree Smith
Corporate Controller5.1yrsno datano data
John Fraser
Chief Scientistno datano datano data

5.1yrs

Average Tenure

60.5yo

Average Age

Experienced Management: PSTV's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc Hedrick
President22.2yrsUS$1.13m0.35%
$ 22.1k
Robert Lenk
Independent Director4.7yrsUS$52.87k0.50%
$ 31.7k
Gregory Petersen
Independent Director4.8yrsUS$80.37k0.83%
$ 52.8k
Richard Hawkins
Independent Chairman of the Board17yrsUS$102.87k0.26%
$ 16.4k
Howard Clowes
Independent Director4.7yrsUS$75.37k0.45%
$ 28.6k
Andrew Brenner
Member of Scientific Advisory Board4.1yrsno datano data
Nicholas Butowski
Member of Clinical Advisory Board4.2yrsno datano data
An van Es-Johansson
Independent Director4.9yrsUS$65.37k0%
$ 0
Russell Lonser
Member of Clinical Advisory Board4.2yrsno datano data
Alireza Mohammadi
Member of Clinical Advisory Board4.2yrsno datano data
Michael Vogelbaum
Member of Clinical Advisory Board4.2yrsno datano data
Manish Aghi
Member of Clinical Advisory Board4.2yrsno datano data

4.4yrs

Average Tenure

67yo

Average Age

Experienced Board: PSTV's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:00
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Plus Therapeutics, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Andrew D'SilvaB. Riley Securities, Inc.
John SavinEdison Investment Research